monoclonal antibodies

The landscape of multiple myeloma treatment has undergone a profound transformation with the advent of monoclonal antibodies (mAbs) targeting CD38. Among the notable breakthroughs, two anti-CD38 mAbs, DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), have been approved for clinical use. These groundbreaking mu...

An antibody is a protein produced by the immune system in response to an infection in the body. Whereas, a monoclonal antibody is a molecule produced in a laboratory specifically designed to enhance the body’s natural immune system response against an invader, such as cancer or an infection. Monoclonal antibodies h...

Multiple Myeloma, the second most common type of malignant cancer first being Non-Hodgkin lymphoma, is a type of cancer which is formed due to the presence of malignant plasma cells in bone marrow. Due to the vigorous proliferation of highly abnormal, unstable cells circulating via the bloodstream and lymph nodes, ...

Apollomics raises USD 100 Million for funding of transpacific cancer R&D plan Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apo...

For all-in-one dialysis system, Outset Medical captures USD 132 Million to extend U.S. expansion Outset Medical bagged USD132 Million in series D capital. This ensued in encouraging the production capabilities and accelerating the commercial expansion for all-in-one dialysis system. The FDA cleared the Tablo Hemodia...